{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:30:31Z","timestamp":1789878631221,"version":"4.0.1"},"reference-count":168,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Hemophilia A and B are uncommon inherited bleeding disorders linked to the X chromosome, resulting from a lack of coagulation factors VIII or IX, respectively. Acknowledged for centuries, hemophilia was historically a dangerous condition lacking effective treatment methods. Significant progress in the 20th century brought about clotting factor alternatives and strategies for preventive treatment. This review offers a refreshed overview of both conventional and new therapies, such as gene therapy, by assessing their advantages, drawbacks, and potential future developments. The narrative review consolidates existing information regarding the pathophysiology of hemophilia, its classification, genotype\u2013phenotype correlations, and advancements in treatment. It examines factor replacement therapies along with newer strategies like non-factor therapies, immune tolerance induction, and gene therapy, while evaluating how these treatments affect patient quality of life and worldwide access to healthcare. While factor replacement therapy is still essential, it entails regular infusions, substantial expenses, and potential risks of inhibitor formation. Innovations such as extended half-life treatments and subcutaneous therapies have enhanced adherence and lowered bleeding rates. Gene therapy has demonstrated the possibility of prolonged natural factor production but continues to encounter issues concerning long-term safety, durability, and accessibility. Newly emerging concerns include the underrepresentation of Hemophilia B in translational research, the immunological challenges associated with vector-based platforms, and significant global disparities in accessing advanced therapies, particularly in low-resource settings. In spite of progress, inequalities in treatment remain, with around 70% of patients globally unable to access crucial therapies.<\/jats:p>","DOI":"10.3389\/fmed.2025.1618464","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:28:24Z","timestamp":1758778104000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care"],"prefix":"10.3389","volume":"12","author":[{"given":"Zaure","family":"Dushimova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Pashimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamilya","family":"Kaibullayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Danyarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmira","family":"Kultanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulnara","family":"Abdilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagima","family":"Mustapayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12288-012-0209-0","article-title":"The history and evolution of the clinical effectiveness of hemophilia type A treatment: a systematic review","volume":"30","author":"Castro","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.2752\/175183511X13173703491117","article-title":"Touching the hem: the thread between garment and blood in the story of the woman with the haemorrhage (mark 5:24b\u201334parr)","volume":"9","author":"Baert","year":"2011","journal-title":"Text"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/0090-3019(86)90070-4","article-title":"Al-Zahrawi and Arabian neurosurgery, 936\u20131013 AD","volume":"26","author":"Al-Rodhan","year":"1986","journal-title":"Surg Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1365-2516.2010.02327.x","article-title":"The \u2018Royal Disease\u2019\u2013Haemophilia A or B? A haematological mystery is finally solved","volume":"16","author":"Lannoy","year":"2010","journal-title":"Haemophilia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1093\/hmg\/ddz157","article-title":"Advances and challenges for hemophilia gene therapy","volume":"28","author":"Batty","year":"2019","journal-title":"Hum Mol Genet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e2020069","DOI":"10.4084\/MJHID.2020.069","article-title":"Gene therapy for hemophilia: facts and quandaries in the 21st century","volume":"12","author":"Arruda","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1055\/s-0037-1604053","article-title":"Emerging therapeutic strategies in the treatment of hemophilia A","volume":"43","author":"Muczynski","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2147\/JBM.S371438","article-title":"Gene therapy and hemophilia: where do we go from here?","volume":"13","author":"Bolous","year":"2022","journal-title":"J Blood Med."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2516.2007.01497.x","article-title":"International workshop on immune tolerance induction: consensus recommendations","volume":"13","author":"Dimichele","year":"2007","journal-title":"Haemophilia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/2040620718796429","article-title":"Practical aspects of extended half-life products for the treatment of hemophilia","volume":"9","author":"Lambert","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1182\/asheducation-2016.1.650","article-title":"New therapies for hemophilia","volume":"2016","author":"Pipe","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1055\/s-0034-1381232","article-title":"The history of hemophilia","volume":"40","author":"Franchini","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1046\/j.1365-2516.1998.00208.x","article-title":"Quality of life during menstruation in patients with inherited bleeding disorders","volume":"4","author":"Kadir","year":"1998","journal-title":"Haemophilia"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2516.2005.01108.x","article-title":"More than menorrhagia: a review of the obstetric and gynecologic manifestations of bleeding disorders","volume":"11","author":"Ah","year":"2005","journal-title":"Haemophilia"},{"key":"ref16","first-page":"427","article-title":"Menorrhagia in adolescents with inherited bleeding disorders","volume":"22","author":"Chi","year":"2009","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1365-3148.2001.00315.x","article-title":"The relationship between ABO histo-blood group, factor VIII and von Willebrand factor","volume":"11","author":"O'Donnell","year":"2001","journal-title":"Transfus Med"},{"key":"ref18","first-page":"2","article-title":"Hemophilia A and B: molecular insights","volume":"110","author":"Lillicrap","year":"2013","journal-title":"Mol Genet Metab"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the ISTH","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/ng1193-236","article-title":"Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A","volume":"5","author":"Lakich","year":"1993","journal-title":"Nat Genet"},{"key":"ref21","first-page":"755","article-title":"Factor VIII gene inversions in severe hemophilia A: molecular characterization and frequency","volume":"4","author":"Antonarakis","year":"1995","journal-title":"Hum Mol Genet"},{"key":"ref22","first-page":"e408","article-title":"Functional independence score in hemophilia: a new performance-based instrument to assess disability in hemophilia","volume":"20","author":"Poonnoose","year":"2014","journal-title":"Haemophilia"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"Berntorp","year":"2012","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1365-2516.2009.02127.x","article-title":"A study of variations in the reported hemophilia A prevalence around the world","volume":"16","author":"Stonebraker","year":"2010","journal-title":"Haemophilia"},{"key":"ref25","year":"2023"},{"key":"ref26","first-page":"729","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"384","author":"Pasi","year":"2021","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5\u2013human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years\u2019 experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"ref30","first-page":"1994","article-title":"Phase 3 study of recombinant factor IX fc fusion protein in hemophilia B","volume":"371","author":"Mahlangu","year":"2014","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in hemophilia B: an orphan disease in need of attention","volume":"138","author":"DiMichele","year":"2007","journal-title":"Br J Haematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e28934","DOI":"10.1002\/pbc.28934","article-title":"Novel treatments for hemophilia through rebalancing of the coagulation cascade","volume":"68","author":"Zhao","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2516.1997.tb00168.x","article-title":"The history of haemophilia","volume":"3","author":"Ingram","year":"1997","journal-title":"Haemophilia"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3891\/acta.chem.scand.12-1878","article-title":"Note on the purification of human antihemophilic globulin","volume":"12","author":"Blomb\u00e4ck","year":"1958","journal-title":"Acta Chem Scand"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/203312a0","article-title":"High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate","volume":"203","author":"Pool","year":"1964","journal-title":"Nature"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJM196512302732701","article-title":"Production of high-potency concentrates of antihemophilic globulin in a closed-bag system","volume":"273","author":"Pool","year":"1965","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF01703241","article-title":"In vitro characteristics of highly purified factor VIII concentrates","volume":"63","author":"Morfini","year":"1991","journal-title":"Ann Hematol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jama.1972.03200180052024","article-title":"Hepatitis and clotting-factor concentrates","volume":"221","author":"Kasper","year":"1972","journal-title":"JAMA"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1055\/s-0038-1661664","article-title":"Hepatitis-free interval after clotting factor therapy in first infused haemophiliacs","volume":"56","author":"Morfini","year":"1986","journal-title":"Thromb Haemost"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1056\/NEJM198502213120805","article-title":"The coincidental appearance of LAV\/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic","volume":"312","author":"Evatt","year":"1985","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood.V67.3.592.592","article-title":"AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations","volume":"67","author":"Ragni","year":"1986","journal-title":"Blood"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1111\/j.1538-7836.2006.02213.x","article-title":"The tragic history of AIDS in the hemophilia population, 1982\u20131984","volume":"4","author":"Evatt","year":"2006","journal-title":"J Thromb Haemost"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1600-0609.1976.tb01115.x","article-title":"Evaluation of prophylactic replacement therapy in haemophilia B","volume":"16","author":"Morfini","year":"1976","journal-title":"Scand J Haematol"},{"key":"ref46","first-page":"317","article-title":"Past, present and future of hemophilia: a narrative review","volume":"15","author":"Franchini","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref47","first-page":"2039","article-title":"Phase 3 study of recombinant factor IX fc fusion protein in hemophilia B","volume":"122","author":"Powell","year":"2013","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/ejh.14176","article-title":"Recombinant factor IX fc for the treatment of hemophilia B","volume":"112","author":"Ljung","year":"2024","journal-title":"Eur J Haematol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia a\u2014safety, efficacy, and development of inhibitors","volume":"328","author":"Lusher","year":"1993","journal-title":"N Engl J Med"},{"key":"ref50","first-page":"275","article-title":"Extended half-life factor VIII and IX preparations: the next generation of hemophilia treatment","volume":"32","author":"Mahlangu","year":"2018","journal-title":"Blood Rev"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Safety and prolonged activity of recombinant factor IX-fc fusion protein in hemophilia B patients","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"key":"ref52","first-page":"547","article-title":"Inhibitor development in patients with haemophilia: pathophysiology and clinical management","volume":"180","author":"Franchini","year":"2018","journal-title":"Br J Haematol"},{"key":"ref53","first-page":"2054","article-title":"Sippet study: plasma-derived versus recombinant factor VIII products and inhibitor development","volume":"374","author":"Gouw","year":"2016","journal-title":"N Engl J Med"},{"key":"ref54","first-page":"782","article-title":"Incidence and risk factors of inhibitors in severe hemophilia A: a real-world prospective cohort study","volume":"27","author":"Kuhn","year":"2021","journal-title":"Haemophilia"},{"key":"ref55","first-page":"1","article-title":"The past and future of inhibitors in hemophilia","volume":"196","author":"Peyvandi","year":"2022","journal-title":"Br J Haematol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0091-6749(98)70061-2","article-title":"IgE-mediated allergy and desensitization to factor IX in hemophilia B","volume":"102","author":"Dioun","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"ref57","first-page":"753","article-title":"The silent progression of joint disease in patients with hemophilia: evidence from imaging studies","volume":"5","author":"Den Uijl","year":"2021","journal-title":"Blood Adv"},{"key":"ref58","first-page":"626","article-title":"Biomarkers and MRI evidence of early joint damage in adolescents and adults with hemophilia A","volume":"122","author":"Lambert","year":"2022","journal-title":"Thromb Haemost"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref60","first-page":"908","article-title":"Recommendations for the implementation of long-acting clotting factor concentrates in clinical practice","volume":"25","author":"Iorio","year":"2019","journal-title":"Haemophilia"},{"key":"ref61","first-page":"1","article-title":"Advances in recombinant factor IX products for hemophilia B","volume":"26","author":"Powell","year":"2020","journal-title":"Haemophilia"},{"key":"ref62","first-page":"1025","article-title":"Fitusiran for the treatment of hemophilia A and B: phase 3 findings","volume":"398","author":"Pasi","year":"2021","journal-title":"Lancet"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): A multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.V130.Suppl_1.85.85","article-title":"HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety, and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia A with inhibitors","volume":"130","author":"Young","year":"2017","journal-title":"Blood"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled fab-arm exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/blood-2019-122817","article-title":"Mim8\u2014a next-generation FVIII mimetic bi-specific antibody\u2014potently restores the hemostatic capacity in hemophilia A settings in vitro and in vivo","volume":"134","author":"Kjellev","year":"2019","journal-title":"Blood"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/jth.15682","article-title":"A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: results from safety studies in cynomolgus monkeys","volume":"20","author":"Lauritzen","year":"2022","journal-title":"J Thromb Haemost"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/rth2.12438","article-title":"MG1113, a specific anti-tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia","volume":"4","author":"Kwak","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1111\/jth.15244","article-title":"Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics","volume":"19","author":"Kwak","year":"2021","journal-title":"J Thromb Haemost"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/hae.14595","article-title":"Befovacimab, an anti-tissue factor pathway inhibitor antibody: early termination of the multiple-dose, dose-escalating phase 2 study due to thrombosis","volume":"28","author":"Mancuso","year":"2022","journal-title":"Haemophilia"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/jth.14207","article-title":"A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"Cardinal","year":"2018","journal-title":"J Thromb Haemost"},{"key":"ref74","first-page":"23","article-title":"Advances in anti-TFPI therapies for hemophilia","volume":"28","author":"Mahlangu","year":"2022","journal-title":"Haemophilia"},{"key":"ref75","volume-title":"Concizumab receives regulatory approval for hemophilia B in multiple regions","year":"2024"},{"key":"ref76","first-page":"310","article-title":"Efficacy and safety of concizumab prophylaxis in hemophilia A and B patients with inhibitors: phase 3 explorer7 trial results","volume":"7","author":"Shapiro","year":"2023","journal-title":"Blood Adv"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJM200106073442301","article-title":"Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A","volume":"344","author":"Roth","year":"2001","journal-title":"N Engl J Med"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1073\/pnas.0812090106","article-title":"Phenotypic correction of murine hemophilia A using an iPS cell-based therapy","volume":"106","author":"Xu","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1111\/hae.12311","article-title":"Production of functional coagulation factor VIII from iPSCs using a lentiviral vector","volume":"20","author":"Kashiwakura","year":"2014","journal-title":"Haemophilia"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"5556","DOI":"10.1182\/bloodadvances.2022008079","article-title":"Intraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice","volume":"6","author":"Joo","year":"2022","journal-title":"Blood Adv."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1161\/ATVBAHA.107.149872","article-title":"Silencing of a targeted protein in vivo platelets using a lentiviral vector delivering short hairpin RNA sequence","volume":"27","author":"Ohmori","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/mt.2008.117","article-title":"Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets","volume":"16","author":"Ohmori","year":"2008","journal-title":"Mol Ther"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1055\/s-0038-1648444","article-title":"Toward gene therapy in hemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells","volume":"67","author":"Hoeben","year":"1992","journal-title":"Thromb Haemost"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/jgm.609","article-title":"Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD\/SCID mice","volume":"6","author":"Kikuchi","year":"2004","journal-title":"J Gene Med"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.ymthe.2004.08.006","article-title":"Sustained phenotypic correction of hemophilia A mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene","volume":"10","author":"Moayeri","year":"2004","journal-title":"Mol Ther"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/j.1538-7836.2003.00534.x","article-title":"Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII","volume":"1","author":"Wilcox","year":"2003","journal-title":"J Thromb Haemost"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/mt.2009.238","article-title":"Supplying clotting factors from hematopoietic stem cell-derived erythroid and megakaryocytic lineage cells","volume":"17","author":"Sadelain","year":"2009","journal-title":"Mol Ther"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1182\/blood-2003-05-1519","article-title":"Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment","volume":"102","author":"Yarovoi","year":"2003","journal-title":"Blood"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/j.1538-7836.2008.02992.x","article-title":"Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors","volume":"6","author":"Gewirtz","year":"2008","journal-title":"J Thromb Haemost"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1172\/JCI28416","article-title":"Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies","volume":"116","author":"Shi","year":"2006","journal-title":"J Clin Invest"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/mt.2013.197","article-title":"Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice","volume":"22","author":"Chen","year":"2014","journal-title":"Mol Ther"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/jth.13436","article-title":"Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice","volume":"15","author":"Baumgartner","year":"2017","journal-title":"J Thromb Haemost"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2010-03-272419","article-title":"Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A","volume":"116","author":"Shi","year":"2010","journal-title":"Blood"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1089\/hum.2012.162","article-title":"Genetically modified adipose tissue-derived stem\/stromal cells in the treatment of hemophilia B","volume":"24","author":"Watanabe","year":"2013","journal-title":"Hum Gene Ther"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.biomaterials.2010.08.094","article-title":"Hierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia B","volume":"32","author":"Coutu","year":"2011","journal-title":"Biomaterials"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"e83280","DOI":"10.1371\/journal.pone.0083280","article-title":"A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A","volume":"8","author":"Tatsumi","year":"2013","journal-title":"PLoS One"},{"key":"ref97","first-page":"678","article-title":"Strategies to modulate immune responses: a new frontier for gene therapy","volume":"24","author":"Arruda","year":"2016","journal-title":"Mol Ther"},{"key":"ref98","year":"2022"},{"key":"ref99","first-page":"2451","article-title":"Hemophilia gene therapy comes of age","volume":"130","author":"George","year":"2017","journal-title":"Blood"},{"key":"ref100","first-page":"1995","article-title":"Gene therapy","volume":"371","author":"High","year":"2014","journal-title":"N Engl J Med"},{"key":"ref101","first-page":"631","article-title":"Progress and challenges in the development of gene therapy for monogenic diseases","volume":"21","author":"Kay","year":"2020","journal-title":"Nat Rev Genet"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2019","journal-title":"Nat Rev Genet"},{"key":"ref103","first-page":"185","article-title":"Gene therapy for hemophilia: clinical trials and regulatory considerations","volume":"132","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref105","first-page":"523","article-title":"Long-term follow-up of liver gene therapy for hemophilia B","volume":"377","author":"Nathwani","year":"2017","journal-title":"N Engl J Med"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5\u2013factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1371596","DOI":"10.3389\/fbioe.2024.1371596","article-title":"Codon-optimization in gene therapy: promises, prospects and challenges","volume":"12","author":"Paremskaia","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1134\/S0006297923120142","article-title":"Viral vectors in gene replacement therapy","volume":"88","author":"Minskaia","year":"2023","journal-title":"Biochem Mosc"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): Normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"e504\u2013e513","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref117","year":""},{"key":"ref118","volume-title":"Fidanacogene elaparvovec (Beqvez): CADTH reimbursement recommendation. CADTH Reimbursement Reviews and Recommendations","year":"2024"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40265-024-02017-4","article-title":"Fidanacogene elaparvovec: First approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2018-99-118256","article-title":"GO-8: preliminary results of a phase I\/II dose escalation trial of gene therapy for hemophilia using a novel human factor VIII variant","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3390\/biom14070854","article-title":"Recent advances in gene therapy for hemophilia: projecting the perspectives","volume":"14","author":"Chernyi","year":"2024","journal-title":"Biomolecules"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/hae.13655","article-title":"Bleeding and safety outcomes in persons with haemophilia A without inhibitors: results from a prospective non-interventional study in a real-world setting","volume":"25","author":"Kruse-Jarres","year":"2019","journal-title":"Haemophilia"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","article-title":"Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project","volume":"129","author":"Manco-Johnson","year":"2017","journal-title":"Blood"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1016\/j.ymthe.2024.12.005","article-title":"China\u2019s first approved gene therapy for hemophilia B: a new era for global AAV-based treatments","volume":"33","author":"Wei","year":"2025","journal-title":"Mol Ther"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/hae.14599","article-title":"Haemophilia gene therapy\u2014update on new country initiatives","volume":"28","author":"Reiss","year":"2022","journal-title":"Haemophilia"},{"key":"ref128","year":""},{"key":"ref129","year":""},{"key":"ref130","year":""},{"key":"ref131","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1182\/bloodadvances.2024014111","article-title":"Adeno-associated virus\u2013based gene therapy for hemophilia A and B: A systematic review and meta-analysis","volume":"8","author":"Deshpande","year":"2024","journal-title":"Blood Adv"},{"key":"ref132","year":""},{"key":"ref133","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1089\/hum.2018.137","article-title":"Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia A","volume":"29","author":"Doering","year":"2018","journal-title":"Hum Gene Ther"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2009.319","article-title":"Recent advances in lentiviral vector development and applications","volume":"18","author":"M\u00e1trai","year":"2010","journal-title":"Mol Ther"},{"key":"ref135","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood-2023-188513","article-title":"Assessment of transduction of CD34+ human hematopoietic stem cells from patients with severe hemophilia A with lentiviral vector carrying a high expression FVIII transgene (CD68-ET3-LV)","volume":"142","author":"Singh","year":"2023","journal-title":"Blood"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa2410597","article-title":"Lentiviral gene therapy for hemophilia A using CD34+ hematopoietic cells","volume":"392","author":"Srivastava","year":"2024","journal-title":"N Engl J Med"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/bioinformatics\/btm589","article-title":"Putative promoter regions of miRNA genes involved in evolutionarily conserved regulatory systems among vertebrates","volume":"24","author":"Fujita","year":"2008","journal-title":"Bioinformatics"},{"key":"ref138","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1371\/journal.pone.0000116","article-title":"miRNA-directed regulation of VEGF and other angiogenic factors under hypoxia","volume":"1","author":"Hua","year":"2006","journal-title":"PLoS One"},{"key":"ref139","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/antibiotics13010076","article-title":"Salmonellosis: an overview of epidemiology, pathogenesis, and innovative approaches to mitigate the antimicrobial resistant infections","volume":"13","author":"Lamichhane","year":"2024","journal-title":"Antibiotics"},{"key":"ref140","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/v15030698","article-title":"Viral vectors in gene therapy: where do we stand in 2023?","volume":"15","author":"Lundstrom","year":"2023","journal-title":"Viruses"},{"key":"ref141","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1111\/jth.12926","article-title":"New approaches to gene and cell therapy for hemophilia","volume":"13","author":"Ohmori","year":"2015","journal-title":"J Thromb Haemost"},{"key":"ref142","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/ijms23020623","article-title":"Ectopic expression of FVIII in HPCs and MSCs derived from hiPSCs with site-specific integration of ITGA2B promoter-driven BDDF8 gene in hemophilia A","volume":"23","author":"Zhao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref143","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.jgg.2022.06.001","article-title":"Long-term correction of hemophilia B through CRISPR\/Cas9 induced homology-independent targeted integration","volume":"49","author":"Chen","year":"2022","journal-title":"J Genet Genomics"},{"key":"ref144","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15252\/emmm.201506039","article-title":"CRISPR\/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse","volume":"8","author":"Guan","year":"2016","journal-title":"EMBO Mol Med"},{"key":"ref145","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00439-017-1801-z","article-title":"CRISPR\/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice","volume":"136","author":"Huai","year":"2017","journal-title":"Hum Genet"},{"key":"ref146","first-page":"7","article-title":"CRISPR\/Cas9-mediated targeted insertion of human F9 achieves therapeutic circulating protein levels in mice and non-human primates","volume":"27","author":"Huang","year":"2019","journal-title":"Mol Ther"},{"key":"ref147","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41434-021-00232-2","article-title":"Cas9-directed in humans\u2014a model to evaluate regulatory T cells in gene therapy?","volume":"28","author":"Wagner","year":"2021","journal-title":"Gene Ther"},{"key":"ref148","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.omtn.2023.03.008","article-title":"In vivo genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector","volume":"32","author":"Lee","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref149","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3324\/haematol.2024.285647","article-title":"Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals","volume":"110","author":"Berger","year":"2025","journal-title":"Haematologica"},{"key":"ref150","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/hae.14012","article-title":"The world federation of hemophilia annual global survey 1999\u20132018","volume":"26","author":"Stonebraker","year":"2020","journal-title":"Haemophilia"},{"key":"ref151","first-page":"3047","article-title":"Impact of hemophilia on health-related quality of life in pediatric population","volume":"85","author":"Elsafy","year":"2021","journal-title":"Egypt J Hosp Med"},{"key":"ref152","doi-asserted-by":"publisher","first-page":"100852","DOI":"10.1016\/j.blre.2021.100852","article-title":"Optimising prophylaxis in haemophilia A: the ups and downs of treatment","volume":"50","author":"Berntorp","year":"2021","journal-title":"Blood Rev"},{"key":"ref153","doi-asserted-by":"publisher","first-page":"632","DOI":"10.18553\/jmcp.2018.24.7.632","article-title":"Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia","volume":"24","author":"Thorat","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"ref154","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/17474086.2021.1957826","article-title":"Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence","volume":"14","author":"Ghosh","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"ref155","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2174\/1874276900802010020","article-title":"Hemophilia: a high cost low volume disease: suitable preventive strategies for developing and developed countries","volume":"2","author":"Ghosh","year":"2008","journal-title":"Open Hematol J"},{"key":"ref156","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/JBM.S291536","article-title":"Optimizing haemophilia care in resource-limited countries: current challenges and future prospects","volume":"14","author":"Ndoumba-Mintya","year":"2023","journal-title":"J Blood Med"},{"key":"ref157","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12288-015-0562-x","article-title":"Management of haemophilia in developing countries: challenges and options","volume":"32","author":"Ghosh","year":"2016","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref158","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1538-7836.2009.03436.x","article-title":"Mild and moderate factor VIII deficiency: inhibitor risks","volume":"7","author":"Aledort","year":"2009","journal-title":"J Thromb Haemost"},{"key":"ref159","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1046\/j.1365-2516.2001.00505.x","article-title":"Development of inhibitors in patients with haemophilia from India","volume":"7","author":"Ghosh","year":"2001","journal-title":"Haemophilia"},{"key":"ref160","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1056\/NEJM197806222982501","article-title":"Asymptomatic structural liver disease in hemophilia","volume":"298","author":"Spero","year":"1978","journal-title":"N Engl J Med"},{"key":"ref161","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/pd.1546","article-title":"First-trimester prenatal diagnosis in haemophilia A and B families\u201410 years experience from a Centre in India","volume":"26","author":"Shetty","year":"2006","journal-title":"Prenat Diagn"},{"key":"ref162","doi-asserted-by":"publisher","first-page":"1450625","DOI":"10.3389\/fpubh.2025.1450625","article-title":"The role of public health in rare diseases: hemophilia as an example","volume":"13","author":"El-Sayed","year":"2025","journal-title":"Front Public Health"},{"key":"ref163","first-page":"4","article-title":"Hemophilia: past, present and future","volume":"27","author":"Mannucci","year":"2021","journal-title":"Haemophilia"},{"key":"ref164","first-page":"6","article-title":"The history of HIV infection in haemophiliacs: a narrative review","volume":"5","author":"Franchini","year":"2020","journal-title":"Ann Blood"},{"key":"ref165","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJM199012273232604","article-title":"Human recombinant DNA\u2013derived antihemophilic factor (factor VIII) in the treatment of hemophilia A","volume":"323","author":"Schwartz","year":"1990","journal-title":"N Engl J Med"},{"key":"ref166","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtha.2022.11.026","article-title":"Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists","volume":"21","author":"Miesbach","year":"2003","journal-title":"J Thromb Haemost"},{"key":"ref167","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"ref168","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/10623320802174464","article-title":"Liver sinusoidal endothelial cells as possible vehicles for gene therapy: A comparison between plasmid-based and lentiviral gene transfer techniques","volume":"15","author":"Paez-Cortez","year":"2008","journal-title":"Endothelium"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1618464\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:28:36Z","timestamp":1758778116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1618464\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":168,"alternative-id":["10.3389\/fmed.2025.1618464"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1618464","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1618464"}}